{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-241970","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2022-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.319467+00:00","generated_at":"2026-06-23T12:14:27.604657+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vera Therapeutics restructures Novartis license milestone payments, issues ~$7M in stock","bullets":["Amended license with Novartis for MAU868; capped total milestone payments at $62.0M.","Issuing 283,034 shares of Class A common stock to Novartis, valued at ~$7M based on closing price plus 20% premium.","Share issuance expected to close on or about September 13, 2022.","Modification adjusts development and regulatory milestone payment structure under the existing license."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-241970","json":"https://secwatch.observer/filing/0001193125-22-241970.json","markdown":"https://secwatch.observer/filing/0001193125-22-241970.md","text":"https://secwatch.observer/filing/0001193125-22-241970.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312522241970/0001193125-22-241970-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312522241970/d265248d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T12:14:27.604657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}